Hopkins Biotech Podcast’s Post

⚫️ Now at ASCRO, Uppsala: Martin Bergstrand explains the possibilities of Model Informed Drug Development, how it can reduce time to market, cost, size of study population and increase probability of success in dose selection, formulation and route of administration among other things, to an engaged audience from different Clinical Research Organizations, (CRO). 🟠 And a tip: There are still (very) few seats left to a workshop on the topic, “An introduction to probabilistic decision support in drug development”, in Rome during PAGE, led by Martin, our CEO Peter Milligan, Chief statistician Richard Anziano and Senior Consultant Giovanni Smania. #cro #lifesciences #biosimulation #biotech

Following recent news from Charles River Laboratories, regarding their continued investment into their Alternative Methods Advancement Project (AMAP), to reduce reliance on animal testing - we are thrilled to share a collaborative #genotoxicity publication between CRL, CN Bio and TwinStrand Biosciences. The publication demonstrates that Liver-on-a-chip is a promising tool for genotoxicity assessment. Click the link to learn more & congrats to all involved! #animalalternatives #organonchip #microphysiologicalsystem

Stop screening & start synthesizing by leveraging the power of SYNTHIA™ retrosynthesis from MilliporeSigma. Register for your free SYNTHIA™ Lite trial access > https://lnkd.in/dZ_EjE39 Quickly find & easily navigate innovative and novel pathways for novel and published target molecules. #retrosynthesis #drugdiscovery #organicchemistry #medicinalchemistry

Are you interested in the drug discovery life cycle and the role of single cell analysis? Watch Jessica Hall, Field application Scientist here at Sphere Fluidics, outlining the process along side the traditional methods vs the picodroplet approach in our first Teach me in 10 video! Watch on demand here: https://lnkd.in/e8G7Jhpm #DrugDiscovery #DrugDevelopment #SingleCellAnalysis #Microfluidics #LabAutomation

👋🏼 Hello toxicologists! We presented at #SOT2024 new data produced by our high-content screening system SydLab™ One for #DART The study highlights the strong advantages of SydLab™ One: 📊 Reproducible and accurate results thanks to standardized protocols 🧪 An automated dosing of chemicals with low liquid consumption  🚀 Multi-phenotypic readouts in real-time in full organisms 🔬 Fully automated high-content screening platform = unlocking #Celegans model as a new #NAMs technology for #EarlyTox SydLab™ One represents the first all-in-one C. elegans microfluidic #labdevice that contributes to the rapid identification of toxic compounds de-risking and accelerating the early stages of discovery pipelines. Missed our presentation? Download the poster here 🔗👉🏼 https://lnkd.in/eVDeJ5rz #toxicology #ReproTox #stressresponse #fluorescence #labtechnology #microfluidics #OoC #HCS #labautomation #AIanalysis

A learning opportunity.

I got 27th place/ 1946 and won a silver medal in a kaggle competition!!! This competition on Kaggle invited participants to forecast the efficacy of potential new medicines. This competition aimed to accelerate drug discovery by enabling more precise predictions of drug outcomes based on chemical data. For our solution, we prepared 2 models, one for which the structure of the molecule is shared in the training set, and another for molecules with unseen structures.  For the shared data, we enhanced accuracy by using a 1D CNN that treats SMILES as strings, incorporating residual connections and attention mechanisms. we used ChemBERTa, capable of transfer learning, and preserved generalization performance by freezing the first three layers during training to retain information from pre-trained molecules. This competition had a huge gap in molecular structure between the Public and Private leaderboards, making it a very "shaky" competition. Despite this, our team managed to create a highly robust model, achieved 8th on the Public and 27th on the private as well. Here is our solution. Any comments or questions are welcome! https://lnkd.in/gjhM5yBj

Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014   The CTA was submitted for a first in human Phase I study to primarily evaluate the safety and tolerability of CS014 in healthy volunteers. The design is a traditional single ascending and multiple ascending dose study for 1 week. Title of the study is “A first-in-human, open-label trial to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of CS014 in healthy volunteers after single and multiple administration”.   Read the full press release here:

Have you ever wondered how your unique genetic makeup influences your response to medications? Join this insightful webinar on Pharmacogenomics—an field that explores the interaction between genetics and drug response. Pharmacogenomics holds the key to personalized medicine, revolutionizing how we prescribe and tailor treatments to individual patients. By understanding genetic variations, healthcare providers can predict how individuals will respond to medications, leading to safer and more effective therapies. You don't want to miss this webinar. #Pharmacogenomics #NextBio #DNAtesting #PersonalizedMedicine #HealthcareInnovation #Workshop #Genetics #DrugResponse #LearningOpportunity